Cat. No. 3607
Chemical Name: 5-[(5-Nitro-2-thiazolyl)thio]-1,3,4
Biological ActivitySelective inhibitor of c-Jun N-terminal kinase (JNK) (IC50 = 0.7 μM). Inhibits the protein-protein interaction between JNK and JIP (IC50 = 239 nM). Displays selectivity over p38 MAPK and Akt. Restores insulin sensitivity in a mouse model of type-2 diabetes.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
De et al (2009) Design, synthesis and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-jun N-terminal kinase. J.Med.Chem. 52 1943. PMID: 19271755.
If you know of a relevant reference for SU 3327 please let us know.
Citations are publications that use Tocris products. Selected citations for SU 3327 include:
Jang et al (2015) Critical role of c-jun N-terminal protein kinase in promoting mitochondrial dysfunction and acute liver injury. J Biol Chem 6 552. PMID: 26491845.
Lo et al (2014) TNF-α induces CXCL1 chemokine expression and release in human vascular endothelial cells in vitro via two distinct signaling pathways. Acta Pharmacol Sin 35 339. PMID: 24487964.
Shaw and Lloyd (2012) Post-transcriptional regulation of placenta growth factor mRNA by hydrogen peroxide. Redox Biol 84 155. PMID: 22683469.
Do you know of a great paper that uses SU 3327 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: SU 3327, supplier, SU3327, JNK, kinases, inhibitors, inhibits, selective, MAPK, Signaling, Signalling, c-Jun, N-Terminal, SAPKs, Stress-Activated, Protein, Mitogen-Activated, Tocris Bioscience, JNK/c-Jun Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective p38α/β inhibitor; orally bioavailableAX 15836
Potent and selective ERK5 inhibitor
Win a $1,000 travel grant
Bio-Techne is offering 10 travel grants of $1,000 for ISSCR 2017.